| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/31/2023 | 102.93% | Benchmark | → $18 | Reiterates | Buy → Buy |
| 07/05/2023 | 102.93% | Benchmark | $140 → $18 | Maintains | Buy |
| 05/15/2023 | -21.08% | Benchmark | → $7 | Reiterates | Buy → Buy |
| 03/09/2023 | -21.08% | Benchmark | → $7 | Reiterates | → Buy |
| 01/31/2023 | -21.08% | Benchmark | $11 → $7 | Reiterates | → Buy |
| 12/15/2021 | 24.01% | Benchmark | → $11 | Initiates Coverage On | → Buy |
| 11/24/2021 | 125.48% | Roth Capital | → $20 | Initiates Coverage On | → Buy |
What is the target price for Biofrontera (BFRI)?
The latest price target for Biofrontera (NASDAQ: BFRI) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $18.00 expecting BFRI to rise to within 12 months (a possible 102.93% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biofrontera (BFRI)?
The latest analyst rating for Biofrontera (NASDAQ: BFRI) was provided by Benchmark, and Biofrontera reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Biofrontera (BFRI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biofrontera, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biofrontera was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.
Is the Analyst Rating Biofrontera (BFRI) correct?
While ratings are subjective and will change, the latest Biofrontera (BFRI) rating was a reiterated with a price target of $0.00 to $18.00. The current price Biofrontera (BFRI) is trading at is $8.87, which is within the analyst's predicted range.